Search research articles
Contact Us
Filters
Showing results (11-20 of 58) with videos related to
Page
of 6
Sort By:
L'Encephale
|
September 16, 2008
[Racing mania does not exist any more, manic-depressive psychosis even more so. How about schizophrenia?]
D Sechter, E Haffen, H Loo
Therapie
|
July 8, 1999
Lack of adverse reaction when switching SSRIs to NASSRIs in polymedicated depressed inpatients
E Haffen, P Vandel, W Regina, et al.
Therapie
|
March 10, 2000
Citalopram pharmacokinetic interaction with clomipramine. UDP-glucuronosyltransferase inhibition? A case report
E Haffen, P Vandel, B Bonin, et al.
Current Pharmaceutical Design
|
February 3, 2007
Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism
P Vandel, J M Talon, E Haffen, et al.
Therapie
|
April 27, 2001
Loxapine side-effects: 3 case reports of hyperleukocytosis
E Haffen, P Vandel, S Vandel, et al.
L'Encephale
|
May 4, 2020
[Challenges for psychotropics in the context of the SARS-Cov-2 pandemic]
H Javelot, P-M Llorca, G Meyer, et al.
L'Encephale
|
June 30, 2000
[Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism]
K Reggiani, P Vandel, E Haffen, et al.
Human Psychopharmacology
|
July 15, 2004
Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients
P Vandel, E Haffen, S Nezelof, et al.
Therapeutic Drug Monitoring
|
June 13, 2000
On the assessment of drug metabolism by assays of codeine and its main metabolites
E Haffen, G Paintaud, M Berard, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
September 23, 2016
Effects of smoking status and MADRS retardation factor on response to low frequency repetitive transcranial magnetic stimulation for depression
E Poulet, F Galvao, E Haffen, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 58) with videos related to
Sort By:
Page
of 6
L'Encephale
|
September 16, 2008
[Racing mania does not exist any more, manic-depressive psychosis even more so. How about schizophrenia?]
D Sechter, E Haffen, H Loo
Therapie
|
July 8, 1999
Lack of adverse reaction when switching SSRIs to NASSRIs in polymedicated depressed inpatients
E Haffen, P Vandel, W Regina, et al.
Therapie
|
March 10, 2000
Citalopram pharmacokinetic interaction with clomipramine. UDP-glucuronosyltransferase inhibition? A case report
E Haffen, P Vandel, B Bonin, et al.
Current Pharmaceutical Design
|
February 3, 2007
Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism
P Vandel, J M Talon, E Haffen, et al.
Therapie
|
April 27, 2001
Loxapine side-effects: 3 case reports of hyperleukocytosis
E Haffen, P Vandel, S Vandel, et al.
L'Encephale
|
May 4, 2020
[Challenges for psychotropics in the context of the SARS-Cov-2 pandemic]
H Javelot, P-M Llorca, G Meyer, et al.
L'Encephale
|
June 30, 2000
[Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism]
K Reggiani, P Vandel, E Haffen, et al.
Human Psychopharmacology
|
July 15, 2004
Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients
P Vandel, E Haffen, S Nezelof, et al.
Therapeutic Drug Monitoring
|
June 13, 2000
On the assessment of drug metabolism by assays of codeine and its main metabolites
E Haffen, G Paintaud, M Berard, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
September 23, 2016
Effects of smoking status and MADRS retardation factor on response to low frequency repetitive transcranial magnetic stimulation for depression
E Poulet, F Galvao, E Haffen, et al.
Page
of 6